Absci Corp. (ABSI)
8.84
-0.71
(-7.43%)
USD |
NASDAQ |
Aug 24, 16:00
8.84
0.00 (0.00%)
After-Hours: 20:00
Absci Debt to Equity Ratio : 0.0156 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0156 |
| March 31, 2026 | 0.0257 |
| December 31, 2025 | 0.028 |
| September 30, 2025 | 0.0296 |
| June 30, 2025 | 0.0428 |
| March 31, 2025 | 0.0449 |
| December 31, 2024 | 0.0564 |
| September 30, 2024 | 0.0595 |
| June 30, 2024 | 0.0602 |
| March 31, 2024 | 0.0593 |
| December 31, 2023 | 0.0906 |
| September 30, 2023 | 0.0904 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0904 |
| March 31, 2023 | 0.0836 |
| December 31, 2022 | 0.0838 |
| September 30, 2022 | 0.0756 |
| June 30, 2022 | 0.0743 |
| March 31, 2022 | 0.0535 |
| December 31, 2021 | 0.0547 |
| September 30, 2021 | 0.056 |
| June 30, 2021 | 4.597 |
| March 31, 2021 | 2.306 |
| December 31, 2020 | 0.2164 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Twist Bioscience Corp. | 0.21 |
| Prime Medicine, Inc. | 2.825 |
| Tenax Therapeutics, Inc. | 0.00 |
| Exicure, Inc. | 0.00 |
| Recursion Pharmaceuticals, Inc. | 0.0728 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 268.92M |
| Total Liabilities (Quarterly) | 22.79M |
| Shareholders Equity (Quarterly) | 246.13M |
| Current Ratio | 10.63 |
| Net Debt Paydown Yield | 0.05% |